Changes in echocardiographic parameters over time in paradoxical low-flow low-gradient aortic stenosis.


Journal

European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788

Informations de publication

Date de publication:
24 07 2023
Historique:
received: 12 01 2023
revised: 08 03 2023
accepted: 26 03 2023
medline: 25 7 2023
pubmed: 3 5 2023
entrez: 3 5 2023
Statut: ppublish

Résumé

To assess the progression of the disease and evolution of the main echocardiographic variables for quantifying AS in patients with severe low-flow low-gradient (LFLG) AS compared to other severe AS subtypes. Longitudinal, observational, multicenter study including consecutive asymptomatic patients with severe AS (aortic valve area, AVA < 1.0 cm²) and normal left ventricle ejection fraction (LVEF ≥ 50%). Patients were classified according to baseline echocardiography into: HG (high gradient; mean gradient ≥ 40 mmHg), NFLG (normal-flow low-gradient; mean gradient < 40 mmHg, indexed systolic volume (SVi) > 35mL/m2), or LFLG (mean gradient < 40 mmHg, SVi ≤ 35 mL/m²). AS progression was analyzed by comparing patients' baseline measurements and their last follow-up measurements or those taken prior to aortic valve replacement (AVR). Of the 903 included patients, 401 (44.4%) were HG, 405 (44.9%) NFLG, and 97 (10.7%) LFLG. Progression of the mean gradient in a linear mixed regression model was greater in low-gradient groups: LFLG vs. HG (regression coefficient 0.124, P = 0.005) and NFLG vs. HG (regression coefficient 0.068, P = 0.018). No differences were observed between the LFLG and NFLG groups (regression coefficient 0.056, P = 0.195). However, AVA reduction was slower in the LFLG group compared to the NFLG (P < 0.001). During follow-up, in conservatively-managed patients, 19.1% (n = 9) of LFLG patients evolved to having NFLG AS and 44.7% (n = 21) to having HG AS. In patients undergoing AVR, 58.0% (n = 29) of LFLG baseline patients received AVR with a HG AS. LFLG AS shows an intermediate AVA and gradient progression compared to NFLG and HG AS. The majority of patients initially classified as having LFLG AS changed over time to having other severe forms of AS, and most of them received AVR with a HG AS.

Identifiants

pubmed: 37131301
pii: 7148598
doi: 10.1093/ehjci/jead067
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1120-1128

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflict of interest: None declared.

Auteurs

Laura Galian-Gay (L)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Gisela Teixidó-Turà (G)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Guillem Casas (G)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Elena Ferrer-Sistach (E)

Department of Cardiology, Hospital Universitari Germans Tries i Pujol, Badalona, Spain.

Cristina Mitroi (C)

Department of Cardiology, Hospital Puerta de Hierro - Majadahonda, Madrid, Spain.

Susana Mingo (S)

Department of Cardiology, Hospital Puerta de Hierro - Majadahonda, Madrid, Spain.

Vanessa Monivas (V)

Department of Cardiology, Hospital Puerta de Hierro - Majadahonda, Madrid, Spain.

Daniel Saura (D)

Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, CIBER-Cardiovascular, Spain.

Bàrbara Vidal (B)

Department of Cardiology, Hospital Clínic de Barcelona, Barcelona, Spain.

Sergio Moral (S)

Department of Cardiology, Hospital Josep Trueta, Girona, Spain.

Francisco Calvo (F)

Department of Cardiology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain.

Violeta Sánchez (V)

Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, CIBERCV, Spain.

Ariana Gonzalez (A)

Department of Cardiology, Hospital Ramón y Cajal, Madrid, Spain.

Gabriela Guzman-Martínez (G)

Department of Cardiology, Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.

Marta Noris Mora (M)

Department of Cardiology, Hospital Universitario Son Espases, Mallorca, Spain.

Miguel Ángel Arnau Vives (MÁ)

Department of Cardiology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Jesús Peteiro (J)

Department of Cardiology, Complexo Hospitalario Universitario A Coruña, Coruña, Spain.

Alberto Bouzas (A)

Department of Cardiology, Complexo Hospitalario Universitario A Coruña, Coruña, Spain.

Teresa González-Alujas (T)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Laura Gutiérrez (L)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Rubén Fernandez-Galera (R)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Filipa Valente (F)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Andrea Guala (A)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Aroa Ruiz-Muñoz (A)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Lydia Dux-Santoy (L)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Ruper Oliveró Soldevila (R)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Augusto Sao Avilés (AS)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

José F Rodríguez Palomares (JF)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Ignacio Ferreira-González (I)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER de Epidemiología y Salud Pública (CIBERESP), Spain.

Artur Evangelista (A)

Department of Cardiology, Hospital Universitari Vall d´Hebron-VIHR, Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER cardiovascular (CIBERCV), Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH